Please login to the form below

Not currently logged in
Email:
Password:

Pipeline

This page shows the latest Pipeline news and features for those working in and with pharma, biotech and healthcare.

Shire warms to Takeda’s latest offer, extending deadline

Shire warms to Takeda’s latest offer, extending deadline

Meanwhile, questions are also being voiced about the value being placed on Shire, and whether its pipeline and R&D capabilities are worthy of such a hefty price tag, even after

Latest news

  • Sanofi appoints ex-Roche Reed as new R&D head Sanofi appoints ex-Roche Reed as new R&D head

    The new broom at Sanofi’s R&D headquarters will give CEO Olivier Brandicourt a chance to further reshape the company, which is in need of new pipeline drugs to compensate

  • Sanofi sells European generics to Advent for $2.4bn Sanofi sells European generics to Advent for $2.4bn

    The restructuring has already seen it bolster its pipeline in rare diseases with the acquisitions of Bioverativ for $11.6bn and Ablynx for 3.9bn after missing out on earlier bids ... Analysts suggest that Sanofi will re-invest the proceeds from the sale

  • Shire rebuffs Takeda bids, as Allergan bows out Shire rebuffs Takeda bids, as Allergan bows out

    Shire's board of directors rejected the bid saying it "significantly undervalued the company, its growth prospects and pipeline”, but noted it has asked its advisors to discuss whether “a further, ... that has since been followed by at least 18 other

  • Alexion adds to pipeline rebuild with $855m Wilson buy Alexion adds to pipeline rebuild with $855m Wilson buy

    Alexion adds to pipeline rebuild with $855m Wilson buy. Also acquires the Swedish group’s lead product for Wilson’s disease. ... and neurologic disorders, and is an important first step in rebuilding our clinical pipeline.”.

  • Celgene bulks up pipeline again with $2.1bn Prothena deal Celgene bulks up pipeline again with $2.1bn Prothena deal

    Celgene bulks up pipeline again with $2.1bn Prothena deal. Acquires candidates with potential in Alzheimer’s, ALS and dementia. ... Celgene has been working to expand its pipeline beyond its core oncology franchise, and the deal with Prothena is the

More from news
Approximately 16 fully matching, plus 1,036 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    And it is a revolution. that is happening right now; there are many such therapies in company pipelines, several of which are.

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    And while the pipeline of new drugs has slowly dwindled, resistance has been on the rise. ... While a new army of smaller biotechs is focusing on AMR innovation, to truly drive research forward and strengthen the dwindling global pipeline, big pharma

  • Health on instalment Health on instalment

    Although so far only a handful of treatments have been approved, an estimated 1, 500 crowd the pipeline, 40 or so of which appear ready for approval in the next few

  • Deal Watch January 2018

    Portfolio/pipeline in haemophilia and other rare blood disorders. Acquisition company. 11, 600. ... Acquisition company. 7, 000. Ablynx/Sanofi. Nanobody platform product pipeline; lead product caplacizumab for acquired thrombotic thrombocytopenic purpura

  • Drug pricing

    Healthcare terms - Drug pricing.

More from intelligence
Approximately 1 fully matching, plus 116 partially matching documents found.

Latest appointments

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy pipeline with another clinical-stage CAR-T candidate from Bluebird Bio. ... Celgene has been adding to its pipeline on all fronts of late, with

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    With expertise in corporate partnering, mergers and acquisitions, pipeline and product portfolio development, legal and IP strategy, Magovcevic-Liebisch has worked in several management roles including executive vice president and chief

  • Leo Pharma appoints new senior vice president Leo Pharma appoints new senior vice president

    We are serving more than 80 million patients worldwide, are launching several products and have an ambitious pipeline and Rhonda is the right person to continue to optimise our operations and

  • Therachon poaches Shire’s Aled Williams Therachon poaches Shire’s Aled Williams

    in developing TA-46, and advancing Therachon’s pipeline of drug candidates that aim to bring a transformational new therapy to those in the achondroplasia community.”.

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    His close engagement with emerging science across biotech and shared focus on patients brings valuable contributions to helping us advance our strategy and pipeline of transformational medicines.”.

More from appointments
Approximately 0 fully matching, plus 169 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 31 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics